Last updated: September 25, 2026
Alfuzosin hydrochloride is an established generic opportunity in benign prostatic hyperplasia (BPH), with commercial value concentrated in extended-release formulation performance, manufacturing efficiency, regulatory interchangeability, and supply reliability. The active ingredient is no longer protected by a meaningful U.S. composition-of-matter barrier. The main technical challenge is reproducing the once-daily modified-release profile while controlling food effects, tablet robustness, dose dumping, and inactive-ingredient variability.
What is the FDA regulatory status of alfuzosin hydrochloride?
Alfuzosin hydrochloride is an orally administered alpha-1 adrenergic receptor antagonist approved for the treatment of signs and symptoms of BPH. The reference product is Uroxatral extended-release tablets, 10 mg, originally approved by the FDA under NDA 021287.[1]
| Attribute |
Alfuzosin hydrochloride |
| Therapeutic category |
Alpha-1 adrenergic receptor antagonist |
| Primary indication |
Signs and symptoms of BPH |
| Reference product |
Uroxatral extended-release tablets |
| U.S. strength |
10 mg extended-release tablet |
| Administration |
Once daily after the same meal |
| Dosage form |
Oral extended-release tablet |
| Generic pathway |
Abbreviated New Drug Application |
| Biosimilar relevance |
None; alfuzosin is a small molecule |
| Key formulation issue |
Controlled release with food-effect management |
The product is administered after the same meal each day because food affects exposure. The extended-release tablet must be swallowed whole and should not be crushed, chewed, or divided.[1]
FDA-approved generic products have established the commercial viability of alfuzosin hydrochloride extended-release tablets. The opportunity is therefore not basic market entry alone. It is differentiated execution in manufacturing cost, product consistency, geographic supply, pharmacy contracting, and potential reformulation.
What excipients are used in alfuzosin hydrochloride extended-release tablets?
The excipient system normally combines a hydrophilic release-control polymer with diluents, granulation or compaction aids, glidants, lubricants, and film-coating materials. Exact compositions differ by manufacturer and may be protected as confidential formulation know-how.
Typical excipient categories include:
| Excipient category |
Common examples |
Primary function |
| Matrix former |
Hypromellose |
Controls hydration, swelling, diffusion, and erosion |
| Diluent |
Mannitol, microcrystalline cellulose |
Provides tablet mass and compression properties |
| Binder |
Povidone |
Improves granule or tablet cohesion |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow |
| Lubricant |
Magnesium stearate |
Reduces tooling friction and ejection force |
| Film former |
Hypromellose |
Creates the protective tablet coating |
| Plasticizer |
Polyethylene glycol |
Improves coating flexibility |
| Opacifier or colorant |
Titanium dioxide, iron oxides |
Appearance and product identification |
Published labeling for Uroxatral and generic products identifies excipients including hypromellose, povidone, magnesium stearate, colloidal silicon dioxide, mannitol, and microcrystalline cellulose, with coating components varying by product.[1,2]
The most commercially important excipient is generally hypromellose or another controlled-release polymer. Its substitution can change gel strength, hydration rate, erosion behavior, dissolution profile, and sensitivity to mechanical damage. Polymer grade, viscosity, particle size, substitution pattern, and supplier variability can matter as much as nominal polymer percentage.
How should the excipient strategy be designed for alfuzosin extended release?
A robust formulation should use the minimum excipient complexity needed to meet dissolution, stability, manufacturability, and bioequivalence requirements. The most defensible strategy is a hydrophilic matrix tablet supported by a conventional direct-compression or dry-granulation process.
Hydrophilic matrix design
Hypromellose is commercially attractive because it is widely available, compendial, scalable, and accepted across major regulatory markets. A polymer matrix can control release through gel formation at the tablet surface. Drug diffusion and polymer erosion then determine the release rate.
The formulation team should screen:
- Low-, medium-, and high-viscosity hypromellose grades
- Polymer concentration and distribution within the tablet
- Particle size and powder rheology
- Direct compression versus dry granulation
- Tablet hardness and porosity
- Lubrication time and magnesium stearate concentration
- Impact of storage humidity on dissolution
Higher-viscosity polymers generally slow release, but polymer concentration and tablet porosity also have material effects. Excessive polymer can produce manufacturing problems, prolonged release, or incomplete release. Insufficient polymer can increase early release and create a dose-dumping risk.
Diluent selection
Mannitol can improve mouthfeel and provide a water-soluble diluent, but its high solubility may accelerate matrix penetration and alter release. Microcrystalline cellulose supports compactibility and can create a stronger, less friable tablet. A mannitol-cellulose blend can balance tablet hardness, porosity, and dissolution.
Calcium phosphate or lactose could provide alternative compression and density profiles, but each introduces formulation tradeoffs. Calcium phosphate may be less suitable where a highly soluble matrix environment is required. Lactose can create compatibility or moisture-management considerations depending on the API and manufacturing process.
Lubrication control
Magnesium stearate is standard, but over-lubrication can reduce tablet tensile strength and slow wetting. The impact can be significant in a hydrophilic matrix because the lubricant may create a more hydrophobic particle surface.
A commercial formulation should establish a narrow lubrication design space and monitor:
- Blend uniformity
- Ejection force
- Tablet tensile strength
- Friability
- Initial release
- Release after accelerated stability
- Dissolution across multiple pH conditions
Film coating
The film coat normally protects the tablet, improves identification, and supports swallowability. It should not become an uncontrolled release barrier unless the product is intentionally designed as a reservoir or coated-matrix system.
A low-weight-gain hypromellose coating is generally easier to scale than a functional polymer coat. Pigment selection can support product differentiation, but unnecessary colorants increase the risk of regional regulatory variation and supply disruption.
What formulation attributes create the largest commercial opportunity?
The principal opportunities are in performance consistency rather than novel pharmacology.
Food-effect control
The product label instructs patients to take alfuzosin extended-release tablets after the same meal each day.[1] A formulation that reduces variability between fed and fasted conditions could have commercial value, but this would likely require substantial clinical and regulatory evidence. The opportunity is technically attractive but more expensive than a standard generic formulation.
A lower-risk strategy is to optimize robustness around the labeled fed condition. Development should evaluate:
- High-fat meals
- Standard meals
- Delayed gastric emptying
- Tablet dispersion after mechanical stress
- Co-administration with common BPH medicines
- Dissolution under biorelevant media
Dose-dumping resistance
The formulation should remain controlled after alcohol exposure, agitation, compression damage, and tablet splitting attempts. Although patients are instructed to swallow the tablet whole, commercial products encounter transportation stress, packaging damage, and variable patient handling.
A matrix system with a strong polymer network can be more resilient than a lightly coated system. That resilience can reduce batch failures and support a stronger regulatory package.
Tablet size and swallowability
BPH patients are often older and may have dysphagia or polypharmacy. Reducing tablet size without compromising the release profile is a practical commercial objective. High-density diluents, optimized granulation, and higher drug loading may reduce tablet dimensions.
A smaller tablet can support pharmacy preference and patient adherence, but the change must remain compatible with bioequivalence and dissolution requirements.
What FDA bioequivalence and Orange Book issues affect alfuzosin generic entry?
Generic alfuzosin hydrochloride products are generally submitted under an ANDA referencing Uroxatral. The regulatory package typically requires pharmaceutical equivalence, comparative dissolution, stability data, and pharmacokinetic bioequivalence.
For an extended-release product, formulation changes can have disproportionate regulatory consequences. A product may match the reference product at a single dissolution condition yet diverge under:
- Multiple pH media
- High agitation
- Alcohol-containing media
- Different apparatus configurations
- Storage conditions
- Tablet hardness ranges
The Orange Book is the relevant FDA source for reference-listed-drug information, patent listings, and exclusivity records.[3] Alfuzosin’s U.S. market is now primarily generic. Historical reference-product patent and exclusivity barriers have expired or ceased to be meaningful barriers to ordinary ANDA entry. The commercial constraint is therefore formulation development and market access, not a continuing composition-of-matter monopoly.
What patents protect alfuzosin hydrochloride products?
Alfuzosin hydrochloride has limited current U.S. patent leverage compared with newer branded medicines. The original active-ingredient and product-development patents were filed decades ago, and the commercial market has transitioned to generic supply.
The relevant IP categories are:
| IP category |
Current commercial significance |
| Active ingredient composition |
Low; historical protection has expired |
| Basic pharmaceutical salt |
Low; alfuzosin hydrochloride is established technology |
| Original extended-release formulation |
Primarily historical |
| Method-of-use patents |
Limited practical barrier for the approved BPH indication |
| Manufacturing process |
Potentially relevant as confidential know-how |
| Polymorph or solid-state IP |
Potentially relevant outside the core U.S. generic market |
| Excipient architecture |
Usually difficult to enforce unless claimed in a valid formulation patent |
| Device or packaging IP |
Limited for conventional tablets |
A formulation patent could still matter if it claims a distinct release architecture, a defined dissolution profile, a novel excipient combination, or a manufacturing process with unexpected performance. In practice, the strongest defensible position is often trade-secret protection over process parameters, polymer grades, granulation endpoints, and control strategies rather than broad patent exclusivity.
Paragraph IV litigation risk is correspondingly lower than for products with active Orange Book formulation patents. Any ANDA sponsor must still conduct a live Orange Book and patent-family review because patent status, listed claims, and litigation records can change by jurisdiction and product.
Which companies are challenging or competing with alfuzosin?
The U.S. competitive field includes generic manufacturers that have received approval for alfuzosin hydrochloride extended-release tablets. Market participation has included large generic companies and regional suppliers, with availability varying by wholesaler contracts and manufacturing continuity.
Competition is based on:
- Wholesale acquisition cost and net pricing
- National pharmacy coverage
- Medicaid and Medicare contracting
- Backorder performance
- Authorized-generic arrangements
- Packaging configurations
- Tablet appearance and pharmacy substitution
- Regulatory inspection history
- API sourcing and dual-supplier capability
Alfuzosin competes clinically with tamsulosin, silodosin, doxazosin, and terazosin. Tamsulosin has a larger established BPH market, while alfuzosin can compete on its uroselective profile and established physician familiarity. Silodosin competes more directly in the selective alpha-1A segment but may carry a different adverse-event and commercial profile.
How does alfuzosin compare with competing BPH drugs?
| Product |
Dosage-form opportunity |
Excipient complexity |
Commercial position |
| Alfuzosin ER |
Once-daily matrix tablet |
Moderate |
Mature generic market |
| Tamsulosin ER |
Modified-release capsule or tablet |
Moderate to high |
Larger generic category |
| Silodosin |
Immediate-release capsule |
Lower formulation complexity |
Selective alpha-1A competitor |
| Doxazosin |
Immediate- or extended-release tablet |
Low to moderate |
Older, price-sensitive market |
| Terazosin |
Immediate-release tablet |
Low |
Low-cost established generic |
Alfuzosin’s advantage for manufacturers is a relatively conventional tablet platform. Its disadvantage is the mature, price-sensitive market and the need to reproduce a food-dependent extended-release profile.
What manufacturing and supply-chain barriers affect alfuzosin?
The API is commercially available from multiple sources, but supplier qualification remains important. Key controls include:
- Assay and related substances
- Residual solvents
- Particle-size distribution
- Bulk density
- Water content
- Salt stoichiometry
- Polymorphic or solid-state consistency
- Nitrosamine and elemental-impurity assessment
- Stability under humidity and light
Excipient supply is less likely to create a fundamental barrier than API supply, but polymer grade changes can alter dissolution. A supplier-change protocol should include comparative powder characterization, pilot-scale compaction, dissolution profiling, and stability testing.
The most valuable manufacturing IP may reside in:
- Polymer pre-blending
- Granulation endpoint control
- Compression-force management
- Lubrication sequence
- Coating weight gain
- In-process dissolution proxies
- Packaging moisture protection
What licensing and commercial deal opportunities exist?
Licensing opportunities are more likely to involve manufacturing and regional commercialization than originator-style patent licensing. Potential structures include:
- Regional rights for countries where alfuzosin remains branded or under-supplied.
- Contract development and manufacturing agreements for extended-release tablets.
- Dual-source API and finished-dose supply arrangements.
- Authorized-generic distribution agreements.
- Formulation technology licensing for smaller tablets or improved release control.
- Co-development of fixed-dose BPH combinations, subject to regulatory and clinical requirements.
- Private-label supply for pharmacy chains and institutional buyers.
The strongest commercial proposition is a dependable, low-cost product with validated supply continuity. A novel excipient system has value only if it lowers manufacturing cost, improves dissolution robustness, reduces tablet size, or creates a regulatory distinction that competitors cannot easily replicate.
What is the revenue exposure and generic launch outlook?
Alfuzosin hydrochloride is unlikely to support premium U.S. pricing without a differentiated product profile. Revenue potential depends on volume, contracting, and manufacturing cost rather than exclusivity.
Standard generic launch
The lowest-risk launch uses a conventional hydrophilic matrix tablet closely aligned with the reference product. This route offers:
- Lower development cost
- Established excipient precedent
- Straightforward commercial positioning
- Limited clinical differentiation
- High price competition
Improved-manufacturing launch
A formulation with improved compression, reduced tablet size, or greater dissolution robustness can support better supply reliability and potentially lower cost of goods. The regulatory pathway remains a standard ANDA if the product does not make a therapeutic claim.
Reformulated or lifecycle product
A product designed to reduce food dependence, improve swallowability, or support combination therapy could create greater value. It would require more extensive clinical, regulatory, and patent planning and could shift the opportunity from ordinary generic competition to a 505(b)(2) or other differentiated pathway, depending on the product claims and formulation changes.
Key Takeaways
- Alfuzosin hydrochloride is a mature small-molecule BPH product with no biosimilar issue.
- The main commercial challenge is extended-release formulation performance, not active-ingredient patent protection.
- Hypromellose, mannitol, microcrystalline cellulose, povidone, colloidal silicon dioxide, and magnesium stearate are representative excipient building blocks.
- Polymer grade, tablet porosity, lubrication, and coating parameters materially affect dissolution.
- Food-effect management is a central product attribute because labeling requires administration after the same meal.
- Standard ANDA entry is feasible, but pricing is likely to be highly competitive.
- The most defensible formulation know-how lies in process controls, release robustness, and supply-chain consistency.
- Higher-value opportunities include smaller tablets, stronger dose-dumping resistance, reduced food sensitivity, regional licensing, and reliable dual-source supply.
- The FDA Orange Book and current litigation databases should control any final patent or Paragraph IV decision.[3]
FAQs About Alfuzosin Hydrochloride Excipient and Commercial Strategy
Can hypromellose be replaced in an alfuzosin extended-release tablet?
Yes, but substitution requires comparative dissolution, stability, and bioequivalence assessment. Polymer viscosity, particle size, substitution level, and hydration behavior can change the release profile.
Is alfuzosin hydrochloride suitable for a fixed-dose combination?
It may be technically suitable, but compatibility, additive blood-pressure effects, food requirements, and separate regulatory claims would require evaluation. A combination product could offer more differentiation than a conventional alfuzosin generic.
Does alfuzosin hydrochloride have an active U.S. composition patent?
The original composition and product-protection period is historical. Current commercial assessment should focus on any live formulation, process, method-of-use, or Orange Book-listed patent rights.
Which excipient is most important for alfuzosin release control?
The release-control polymer, commonly hypromellose, usually has the greatest direct effect. Tablet porosity, diluent ratio, compression force, and lubrication can materially modify the polymer’s behavior.
Is a 505(b)(2) product more attractive than an ANDA for alfuzosin?
An ANDA is generally more efficient for a conventional equivalent product. A 505(b)(2) strategy becomes more attractive only when the sponsor can support a meaningful change, such as altered release, reduced food sensitivity, a new dosage form, or a clinically relevant combination.
References
- U.S. Food and Drug Administration. (2011). Uroxatral (alfuzosin hydrochloride) extended-release tablets, prescribing information.
- National Library of Medicine. (n.d.). DailyMed: Alfuzosin hydrochloride extended-release tablets.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2009). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products.
- U.S. Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary.
